Yahoo
    Tokyo - Delayed Quote JPY

    Kyowa Kirin Co., Ltd. (4151.T)

    2,464.00 +62.50 (+2.60%)
    At close: October 30 at 3:30:00 PM GMT+9
    Loading Chart for 4151.T
    Chart Range Bar
    Interval:
    In partnership with ChartIQ

    Recent News

    Three-Year Real-World Study Compares Burosumab Treatment with Oral Phosphate and Active Vitamin D in Adults with XLH

    Three-Year Real-World Study Compares Burosumab Treatment with Oral Phosphate and Active Vitamin D in Adults with XLH
    GlobeNewswire 17d ago
    Is Kyowa Kirin (TSE:4151) A Bargain Following Its Share Price Pullback?

    Is Kyowa Kirin (TSE:4151) A Bargain Following Its Share Price Pullback?
    Simply Wall St. 1mo ago
    Kyowa Kirin Announces Agreement with U.S. Administration to Reduce Treatment Costs for Americans

    Kyowa Kirin Announces Agreement with U.S. Administration to Reduce Treatment Costs for Americans
    GlobeNewswire 1mo ago
    FDA Selects Kyowa Kirin for PreCheck Pilot Program to Accelerate Manufacturing Timelines and Enhance Supply Chain Resilience

    FDA Selects Kyowa Kirin for PreCheck Pilot Program to Accelerate Manufacturing Timelines and Enhance Supply Chain Resilience
    GlobeNewswire 3mo ago
    Kyowa Kirin to Present New Complementary Evidence Further Defining Clinical Utility of Mogamulizumab in Cutaneous T-Cell Lymphoma at 2026 WCCL

    Kyowa Kirin to Present New Complementary Evidence Further Defining Clinical Utility of Mogamulizumab in Cutaneous T-Cell Lymphoma at 2026 WCCL
    GlobeNewswire 4mo ago
    Romiplate Sales Forecast and Market Size Analysis Report 2026-2034 with Focus on United States, Germany, France, Italy, Spain, United Kingdom, and Japan

    Romiplate Sales Forecast and Market Size Analysis Report 2026-2034 with Focus on United States, Germany, France, Italy, Spain, United Kingdom, and Japan
    GlobeNewswire 5mo ago
    Kyowa Kirin and Kura Oncology Initiate Japanese Phase 2 Registration-Directed Trial of Ziftomenib in R/R NPM1-m AML

    Kyowa Kirin and Kura Oncology Initiate Japanese Phase 2 Registration-Directed Trial of Ziftomenib in R/R NPM1-m AML
    GlobeNewswire 6mo ago
    Kyowa Kirin, Knight agree Latin American distribution deal for mogamulizumab

    Kyowa Kirin, Knight agree Latin American distribution deal for mogamulizumab
    Hospital Management 1mo ago
    Kyowa Kirin, Knight agree Latin American distribution deal for mogamulizumab

    Kyowa Kirin, Knight agree Latin American distribution deal for mogamulizumab
    Pharmaceutical Technology 1mo ago
    Kyowa Kirin and Knight Therapeutics Enter Into Exclusive Distribution Agreement for POTELIGEO® (mogamulizumab) for Cutaneous T-Cell Lymphoma (CTCL) Patients Across Latin America

    Kyowa Kirin and Knight Therapeutics Enter Into Exclusive Distribution Agreement for POTELIGEO® (mogamulizumab) for Cutaneous T-Cell Lymphoma (CTCL) Patients Across Latin America
    Business Wire 1mo ago
    Kura Oncology and Kyowa Kirin to Present Updated Frontline Ziftomenib / 7+3 Combination Data at EHA 2026 Congress

    Kura Oncology and Kyowa Kirin to Present Updated Frontline Ziftomenib / 7+3 Combination Data at EHA 2026 Congress
    GlobeNewswire 5mo ago

    Related Tickers

    Mobilize your Website
    View Site in Mobile | Classic
    Share by: